Clinical trials: GAD
Generalized Anxiety Disorder
Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder
This is a randomized double-blind placebo-controlled phase 3 clinical trial to further validate the effectiveness and safety of Shugan Jieyu Capsules in treating generalized anxiety disorder.
- Trial name
- NCT05772104
- Testing
- Shugan Jieyu Capsules
- Where
- China
- Volunteers
- 495 people
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.
Generalized Anxiety Disorder
A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder
This is a global, phase 3, randomized, double-blind, parallel-group, 3-arm, placebo-controlled, multicenter study designed to compare the efficacy, safety, and tolerability of fixed doses of SEP-363856 (50 and 75 milligrams per…
- Trial name
- NCT07759128
- Testing
- SEP-363856
- Where
- 17 sites in United States
- Volunteers
- 576 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
GAD subjects maintained on a stable dose of alprazolam for at least four weeks who meet eligibility criteria will be randomized to receive pregabalin vs matching placebo while simultaneously tapering off of alprazolam over 6…
- Trial name
- GAD (NCT00368745)
- Testing
- Pregabalin
- Where
- 21 sites in Costa Rica, Czechia and 5 more
- Volunteers
- 108 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Generalized Anxiety Disorder
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages 18 to 65, with generalized anxiety disorder.
- Trial name
- NCT00658372
- Testing
- PD 0332334, Paroxetine
- Where
- 33 sites in United States, Hungary and 2 more
- Volunteers
- 360 people
- Sponsor
- Pfizer
General Anxiety Disorder
Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).
- Trial name
- NCT00233675
- Testing
- GABITRIL (tiagabine hydrochloride; CEP-6671)
- Where
- 28 sites in United States
- Sponsor
- Cephalon
ADHD, Anxiety
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
- Conditions
- ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
- Trial name
- NCT06973577
- Testing
- Centanafadine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- CAR aGAD Ph 2 (NCT04965272)
- Testing
- Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day
- Where
- 36 sites in United States
- Sponsor
- AbbVie
Generalized Anxiety Disorder
Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.
- Trial name
- NCT00595231
- Testing
- SYN111
- Where
- 2 sites in United States
- Volunteers
- 239 people
- Sponsor
- Biotie Therapies Inc.
Anxiety Disorders
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
The purpose of the study is to evaluate the efficacy and safety of SR58611A in patients with Generalized Anxiety Disorder. The primary objective is to evaluate the efficacy of a 350 mg and 700 mg dose of SR58611A compared to…
- Trial name
- ELECTRA (NCT00332891)
- Testing
- SR58611A
- Where
- 5 sites in Bulgaria, Croatia and 3 more
- Volunteers
- 508 people
- Sponsor
- Sanofi
Anxiety
A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with generalized anxiety disorder.
- Trial name
- NCT00390650
- Testing
- Saredutant
- Where
- 2 sites in United States, Canada
- Volunteers
- 366 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder.
- Trial name
- TITANIUM (NCT00329264)
- Testing
- Quetiapine fumarate
- Where
- 58 sites in United States
- Volunteers
- 876 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
MDD, Anxiety Disorders
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression coexisting with generalized anxiety disorder.
- Trial name
- RECONNECT (NCT04220996)
- Testing
- Vortioxetine
- Where
- 21 sites in Estonia, France and 4 more
- Volunteers
- 100 people
- Sponsor
- H. Lundbeck A/S
Anxiety Disorders
Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder
The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.
- Trial name
- NCT00715039
- Testing
- lorazepam, paroxetine
- Where
- 15 sites in United States
- Volunteers
- 169 people
- Sponsor
- Pfizer
Generalized Anxiety Disorder
A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder
This is a global, Phase 3, multicenter, open-label extension trial designed to evaluate the long-term safety, tolerability and efficacy of SEP-363856 administered at doses of 50 milligrams (mg) or 75 mg per day in adult…
- Trial name
- NCT07786454
- Testing
- SEP-363856
- Where
- 2 sites in United States
- Volunteers
- 1,120 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Type 1 Diabetes Mellitus
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)
The purpose of this study is to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.
- Trial name
- NCT00723411
- Testing
- rhGAD65
- Where
- 70 sites in Finland, France and 7 more
- Volunteers
- 334 people
- Sponsor
- Diamyd Therapeutics AB
Generalized Anxiety Disorder (GAD)
EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
To evaluate the efficacy of EDG004 compared to placebo for the treatment of adult patients with GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 5th Ed.
- Trial name
- NCT02305797
- Testing
- Extended-release lorazepam
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Edgemont Pharmaceuticals, LLC
Depression, Anxiety Disorders
Prospective Study of the Evaluation of Disease contRol and the Quality of Life of Patients With depressiOn and With or Without aNxiety disOrders in the Greek populatIon
Depression is a psychiatric disorder that affects mood, thoughts and is usually accompanied by physical annoyances. It affects the person's eating habits, his sleep, the way he sees himself and the way he thinks and understands.
- Trial name
- PRONOI (NCT03317262)
- Where
- Greece
- Volunteers
- 800 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Generalized Anxiety Disorder
Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body
The purpose of this study is to estimate the effects of multiple doses of cimetidine on the pharmacokinetics of a single dose of PD 0332334 and to evaluate the safety and tolerability of PD 0332334 when co-administered with…
- Trial name
- NCT00800280
- Testing
- PD 0332334, cimetidine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Generalized Anxiety Disorder
A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.
The study aims to evaluate the efficacy and safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets compared to placebo in adults participants with generalized anxiety disorder over a period of 8 weeks.
- Trial name
- NCT05970510
- Testing
- Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg, Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg
- Where
- China
- Volunteers
- 555 people
- Sponsor
- Luye Pharma Group Ltd.